

SCRI to Use DxTerity Reagents in Cardiac Test

December 10, 2008
By a GenomeWeb staff reporter
GenomeWeb News

NEW YORK (GenomeWeb News) – DxTerity Diagnostics today said that the Scottsdale Clinical Research Institute in Arizona will use the firm's Quenched Auto Ligating reagents for development of a microRNA-based cardiac test.

The test will measure the expression of a microRNA biomarker in heart biopsy tissue samples, which has been shown to correlate with post-operative heart arrhythmia. DxTerity said that SCRI will use its QUAL reagents to validate the biomarker's ability to reveal at-risk patients before an arrhythmia strikes.

"SCRI and DxTerity have established an alliance to develop bioassay platforms supporting the vision of personalized medicine," said Mark Slater, VP of research at SCRI. "Our shared goal is to accelerate the development and use of novel predictive biomarkers by physicians, and to improve patient outcomes."

Rancho Dominguez, Calif.-based DxTerity noted that the project is being partially funded by the Ibis Foundation of Arizona.

###